BioCardia, Inc. (BCDA) stock
Close on Nov 11, 2026Market cap $13.95MP/E –Yield –
BioCardia, Inc. saw revenue fall 100.0% to $0 over fiscal 2025. Free cash flow was -$7.57M. At the latest close the market valued the company at $13.95M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $13.95M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 5.17
- Dividend yield
- –
- Free cash flow yield
- -54.27%
Fundamentals
- Revenue
- $0
- Net income
- -$7.34M
- EPS, diluted
- -$0.77
- Free cash flow
- -$7.57M
- Book value per share
- $0.22
- Diluted shares
- 12M
Trading
- Next earnings
- Nov 11, 2026 (estimated, after the close)
- Previous close
- $0.93
- Open
- $0.93
- Day's range
- $0.90 – $0.98
- Volume
- 58,184
- Average volume (20 days)
- 115,998
- Beta (5 years)
- 1.02
- 52-week range
- $0.75 – $1.80
- RSI (14 days)
- 47.2
- Volatility (1 year)
- 67.5%
- Relative volume
- 0.23×
- WACC
- 10.0%
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | BCDA | S&P 500 | Difference | BCDA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -11.4% | -2.4% | −9.0 pts | ||
| 3 months | -1.1% | -1.2% | +0.0 pts | ||
| Year to date | -26.3% | +12.3% | −38.6 pts | ||
| 1 year | -30.7% | +12.4% | −43.1 pts | ||
| 3 years | -84.2% | +78.8% | −163.1 pts | -46.0% | +21.4% |
| 5 years | -97.6% | +75.2% | −172.8 pts | -52.5% | +11.9% |
| 10 years | -99.6% | +311.1% | −410.7 pts | -42.7% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases BioCardia filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- News
- News
About BioCardia
Biological Products, (No Diagnostic Substances)
BioCardia, Inc. is a clinical-stage biotechnology company that develops cellular and cell-derived therapeutics to treat cardiovascular and pulmonary conditions. The company's pipeline includes the CardiAMP autologous mononuclear cell therapy platform, which targets ischemic heart failure with reduced ejection fraction and refractory angina from chronic myocardial ischemia. It also develops an allogeneic mesenchymal stem cell platform for heart failure and acute respiratory distress syndrome. In addition, the company produces the Helix transendocardial biotherapeutic delivery system, a catheter-based platform for delivering therapies into heart tissue. BioCardia serves patients suffering from severe cardiac diseases and collaborates with biopharmaceutical partners by providing delivery systems and specialized development services.
Company profile, executives and historyBioCardia stock: common questions
What is BioCardia's stock price?
BCDA closed at $0.92 on Nov 11, 2026, down 0.91% on the day. Over the past 52 weeks it traded between $0.75 and $1.80.
What is BioCardia's market cap?
BioCardia was worth $13.95M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is BCDA's P/E ratio?
BioCardia lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.77), so it has no meaningful P/E ratio.
How much revenue does BioCardia make?
BioCardia reported revenue of $0 for fiscal 2025, down 100.0% from a year earlier.
Does BioCardia pay a dividend?
No. BioCardia has not paid a cash dividend over the last twelve months.
When does BioCardia report earnings next?
BioCardia is expected to report Q3 FY2026 results on Nov 11, 2026, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has BCDA stock performed over the past year?
Including dividends, BCDA returned -30.7% over the past year, against +12.4% for the S&P 500.
How many BCDA shares are sold short?
1M shares were sold short at the latest FINRA report, 5.50% of the float, or 6.3 days of average trading volume.
Who are BioCardia's competitors?
Companies most similar to BioCardia by business, industry and size include CELZ, ALLO, SNTI, TLPH, TCRT.
See a number that looks wrong?